Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
69.50    1.00 (1.46%)
Bid:
68.00
Ask:
71.00
Spread: 3.00 (4.412%)
Market Cap: £316.30m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Re Agreement

7 Jan 2008 10:50

Avacta Group plc

Strategic Alliance

Broader service offering augments market position

Avacta Group plc ("Avacta"), which provides novel detection and analysis technology for the pharmaceutical, defence & security and clinical diagnostics markets, announces an agreement with Agenda 1 Analytical Services Ltd ("Agenda 1").

Agenda 1 provides a wide range of analytical techniques and services from bespoke laboratories located close to Avacta in Bradford, UK. Agenda 1 provides a complementary service offering to Avacta by focusing on small molecule therapeutics, whereas Avacta's strength is in the provision of expert analysis to companies developing large molecule biopharmaceuticals. Consequently, the agreement provides an immediate synergy allowing Avacta to offer an enhanced analytical service to a much wider base of pharmaceutical companies along with access to expertise, resources and technology not available in-house.

The Directors of Avacta believe that this enhanced product offering will enable accelerated growth of the analytical services business because it affords Avacta the ability to offer a greater range of the services required by the pharmaceutical industry. There will be no consideration payable by Avacta for this sharing of services.

Professor Alastair Smith, Chief Executive Officer, Commented:

"Avacta Analytical Limited, Avacta's technical services subsidiary, has made very good progress in its provision of analytical services to the biopharmaceutical sector but we are aware that some potential clients require an even broader range of services than we have been able to offer to date. Today's agreement allows us to extend our services and cover a greater range of the pharmaceutical industry's requirements and my expectation is that this will lead to more rapid growth in the services business of the Group."

7 January 2008Enquiries:Avacta Group plc Tel: 0870 835 4367 Russell Hodgetts Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk WH Ireland Ltd (Nominated Adviser) Tel: 0161 832 2174 David Youngman/Robin Gwyn BankOra Ltd Tel: 020 7562 4700 Michael Brennan/Henry Turcan Notes to Editors:About Avacta

Avacta was spun-out from the University of Leeds in 2004 by its current management team as a biophysics company, with the aim of combining the disciplines of physics and biology to develop innovative technologies and expert technical services to address needs in the pharmaceutical, defence and clinical diagnostics markets. Avacta has a core bio-analytical technology development programme addressing the needs of the biopharmaceutical sector to fully characterise their new products at the earliest stage in their development to reduce the risk of late stage failure. High value solutions in defence and clinical diagnostics are also being provided by Avacta's development programmes.

A successful and growing part of the Avacta business model is its technical services arm, Avacta Analytical Ltd which is focused on providing leading edge contract research to the biopharmaceutical and healthcare/personal-care materials sectors. Avacta listed on AIM in August 2006 through the reverse takeover of Readybuy plc which changed its name to Avacta Group plc.

About Agenda 1

Agenda 1 grew from the analytical laboratories of Nektar Therapeutics (UK) Ltd - (a.k.a. Bradford Particle Design Ltd). The team was formed to utilise their experience as a development group supporting both new technologies and new pharmaceutical products working from early stage project initiation up to and including enabling the release of material for clinical trials.

Agenda 1's client base ranges from major pharmaceutical companies through to virtual companies, and emerging and growing Bio-Pharma businesses. Agenda 1 has developed a number of flexible approaches to help clients access their lab facilities. These include the option to place contract staff into the laboratories via a unique structure with Synergy Outsourcing, a company specialising in scientific personnel. Agenda 1 has also recently launched an innovative "Lab Time-Share" approach, which saw the company awarded the prestigious Royal Society of Chemistry "SME of the month" award for July 2007.

AVACTA GROUP PLC
Date   Source Headline
25th Apr 20074:29 pmPRNHolding(s) in Company
10th Apr 200711:59 amPRNDirector Shareholding
5th Apr 200712:13 pmPRNTotal Voting Rights
4th Apr 20077:00 amPRNPlacing and Appointment of joint broker
4th Apr 20077:00 amPRNProduct Launch
30th Jan 20071:51 pmPRNInterim Results
21st Dec 20068:44 amPRNTotal Voting Rights
29th Nov 20067:00 amPRNRe Agreement
20th Oct 20063:40 pmRNSChange of accounting ref date
11th Oct 200611:12 amRNSAnnual Report and Accounts
19th Sep 20067:00 amPRNRe Agreement
24th Aug 20067:00 amPRNCollaboration Agreement
9th Aug 20068:03 amPRNSupplementary consideration shares
8th Aug 20068:00 amPRNFirst Day of Dealings
7th Aug 200612:58 pmRNSResult of EGM
21st Jul 200610:15 amRNSSch 1 - Readybuy PLC
14th Jul 20062:20 pmRNSFinal Results
14th Jul 200612:00 pmRNSRestoration - Readybuy PLC
14th Jul 200612:00 pmRNSPropsd Aqstn & notice of EGM
13th Jul 20069:30 amRNSStmnt re Proposed Transaction
13th Jul 20068:05 amRNSSuspension - Readybuy PLC
7th Jul 20064:07 pmRNSDirectorate Change
5th May 200611:24 amRNSResult of EGM
19th Apr 20063:13 pmRNSFurther re Issue of Equity
19th Apr 20068:08 amRNSHolding(s) in Company
13th Apr 20065:28 pmRNSHolding(s) in Company
12th Apr 20067:44 amRNSIssue of Equity
9th Mar 20062:19 pmRNSHolding(s) in Company
26th Jan 20068:23 amRNSInterim Results
24th Aug 20057:00 amRNSFinal Results
25th Jul 20057:57 amRNSBoard change & trading update
17th Jun 200511:09 amRNSBusiness Strategy
25th May 20054:55 pmRNSIssue of Equity
11th Apr 200511:00 amRNSEGM Statement
23rd Mar 20059:22 amRNSIssue of Equity
15th Mar 20053:32 pmRNSNotice of EGM
28th Jan 20054:48 pmRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.